CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 12.65: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
566.52MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.96xvs all stocks
52-Week Change
59.85%vs all stocks
Market Capitalization
566.52MUSDvs all stocks (USD)
Enterprise Value
349.48MUSDvs all stocks (USD)
Forward P/E
-5.47xvs Biotechnology peers
Price to Book (MRQ)
2.06xvs Biotechnology peers
Enterprise to EBITDA
-2.96xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-27.98%vs Biotechnology peers
Return on Equity (TTM)
-45.31%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
-88.38MUSDvs all stocks (USD)
EBITDA (TTM)
-117.99MUSDvs all stocks (USD)
Net Income (TTM)
-111.11MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-86.82MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-48.08MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-103.33MUSDvs all stocks (USD)
Pre-tax Income
-90.35MUSDFY2025 · Dec 31, 2025Net Income
-90.35MUSDFY2025 · Dec 31, 2025EBIT
-90.35MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-87.25MUSDFY2025 · Dec 31, 2025Research & Development
75.01MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
28.32MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.55MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
5.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-90.35MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-75.37MUSDFY2025 · Dec 31, 2025Free Cash Flow
-76.56MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
104.18MUSDFY2025 · Dec 31, 2025Interest Paid
5.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-90.35MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.09MUSDFY2025 · Dec 31, 2025Stock-based Compensation
14.18MUSDFY2025 · Dec 31, 2025Other Non-cash Items
51.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
627.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.98MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.18MUSDFY2025 · Dec 31, 2025Purchase of Investments
-269.51MUSDFY2025 · Dec 31, 2025Sale of Investments
284.70MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
14.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-61.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-241.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
30.08MUSDFY2025 · Dec 31, 2025Shares Outstanding
15.83MSharesUpdated Sep 28, 2026Float Shares
11.33MSharesUpdated Sep 28, 2026Shares Short
3.28MSharesUpdated Sep 28, 2026Short Ratio
15.20daysvs all stocks
Short % of Shares Outstanding
19.45%vs all stocks
% Held by Insiders
6.98%vs all stocks
% Held by Institutions
88.93%vs all stocks
Total Cash (MRQ)
225.39MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
11.26USDUpdated Sep 28, 2026Total Debt (MRQ)
8.35MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0384xvs Biotechnology peers
Current Ratio (MRQ)
10.64xvs Biotechnology peers
Book Value per Share (MRQ)
13.72USDUpdated Sep 28, 2026Total Assets
288.60MUSDvs all stocks (USD)
Total Current Assets
271.77MUSDFY2025 · Dec 31, 2025Total Liabilities
23.72MUSDFY2025 · Dec 31, 2025Total Non-current Assets
16.83MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
7.31MUSDFY2025 · Dec 31, 2025Total Current Liabilities
16.41MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
103.84MUSDFY2025 · Dec 31, 2025Other Short-term Investments
165.17MUSDFY2025 · Dec 31, 2025Accounts Payable
1.95MUSDFY2025 · Dec 31, 2025Short-term Debt
3.70MUSDFY2025 · Dec 31, 2025Other Current Liabilities
564.00KUSDFY2025 · Dec 31, 2025Long-term Debt
7.25MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
51.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-352.65MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
264.89MUSDvs all stocks (USD)
52-Week Low
15.93USDUpdated Sep 28, 202652-Week High
43.66USDUpdated Sep 28, 202652-Week Change
59.85%vs all stocks
Beta
1.96xvs all stocks
50-Day MA
35.85USDUpdated Sep 28, 2026200-Day MA
27.02USDUpdated Sep 28, 2026Avg 10-Day Volume
453.47KSharesUpdated Sep 28, 2026Avg 30-Day Volume
294.64KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-5.04USDUpdated Sep 28, 2026Other Income / Expense
1.44MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 12.65: safe zoneNotable
Altman Z-Score: 12.65
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Nanjing Well Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Starry Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Scitop Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Allogene Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Assure Tech Hangzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Orient Gene Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Monopar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Gujarat Themis Biosyn Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Hicin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ChemoCentryx Inc
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Beijing SDL Technology Co. Ltd.
1 interpretationLow-Leverage Liquidity Configuration
Sichuan Guoguang Agrochemical Co. Ltd.
1 interpretationLow-Leverage Liquidity Configuration
Doctorglasses Chain Co. Ltd.
1 interpretationLow-Leverage Liquidity Configuration